VANCOUVER, British Columbia, Jan. 7, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the 4th Annual OneMedForum Emerging Company Finance Conference on Wednesday, January 12 at 8:10 AM PST. The conference is being held at the Sir Francis Drake Hotel in San Francisco.
Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer based medical devices rendering them antimicrobial. He will also present the multibillion dollar market potential of this technology.
"I anticipate a very positive response from our presentation at OneMedForum," said Rewcastle. "This conference is attended principally by CEOs and Investors. The Enox story is attractive to both these audiences from a licensing and investment prospective, respectively."About Enox Biopharma, Inc.
Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer or silicone based medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forwar
|SOURCE Enox Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved